# FDA SaMD Submission Readiness Report
**Device:** Test Device
**Report Generated:** 2026-04-10T11:45:49.009391
**Overall Completion:** 36.2% (21/58 items)

## BLOCKERS (Critical Missing Items)
18 blocker items require immediate attention:
- [ml-003] **AI/ML-Specific**: Algorithm performance metrics established and validated
  - Evidence: Validation study with independent test set; performance metrics (sensitivity, specificity, AUROC, AUC-PR, F1 score); comparison to predicate/standard of care
  - Reference: FDA Proposed AI/ML Regulation (2023 draft)
- [ml-008] **AI/ML-Specific**: PCCP (Post-Market Continuous Learning Plan) if modifications planned
  - Evidence: Approved PCCP document defining pre-approved modifications, modification protocols, performance monitoring, impact assessment, or justification that PCCP not required
  - Reference: FDA Proposed AI/ML Regulation (2023 draft)
- [ce-001] **Clinical Evidence**: Clinical evaluation report prepared
  - Evidence: Comprehensive clinical evaluation report reviewing literature, predicate device data, and clinical validation study results; discussion of safety and efficacy
  - Reference: 21 CFR 807.87(e) - Clinical Data
- [ce-002] **Clinical Evidence**: Clinical validation study conducted (if required)
  - Evidence: Prospective or retrospective clinical study with predefined protocol; IRB approval; informed consent (if applicable); statistical analysis plan; results report
  - Reference: 21 CFR Part 56 - Institutional Review Boards
- [ce-003] **Clinical Evidence**: Performance statistics documented and justified
  - Evidence: Sensitivity, specificity, predictive values, confidence intervals; comparison to predicate or reference standard; subgroup analysis; statistical power justification
  - Reference: FDA Guidance - Analytical Validation of Diagnostic Tests
- [ce-004] **Clinical Evidence**: Substantial equivalence established (510k only)
  - Evidence: Substantial equivalence assessment comparing device to predicate on intended use, technology, and performance; explanation of any differences
  - Reference: 21 CFR 807.87(a) - 510(k) Summary
- [dc-003] **Design Controls**: Design outputs documented and reviewed for adequacy
  - Evidence: Design output specifications (algorithms, architecture, file formats) traced to inputs; design output review checklist
  - Reference: 21 CFR 820.30(d) - Design Output
- [dc-006] **Design Controls**: Design validation completed (does device meet user needs?)
  - Evidence: Validation plan and report; clinical testing, field studies, or real-world performance data; statistical analysis
  - Reference: 21 CFR 820.30(g) - Design Validation
- [rm-004] **Risk Management**: Risk control measures designed and evaluated
  - Evidence: Risk control plan specifying mitigation for each significant hazard; evidence of residual risk evaluation; traceability from hazard to control to design
  - Reference: ISO 14971:2019 Section 4.4
- [rm-005] **Risk Management**: Residual risk evaluation and overall risk analysis completed
  - Evidence: Residual risk report; evidence that residual risks are acceptable; overall risk benefit analysis; summary of risks considered acceptable
  - Reference: ISO 14971:2019 Section 4.5
- [rm-006] **Risk Management**: Risk management report prepared
  - Evidence: Comprehensive risk management report summarizing hazards, risks, controls, and residual risks; approvals from relevant stakeholders
  - Reference: ISO 14971:2019 Section 4.6
- [sl-005] **Software Lifecycle**: Detailed software design completed
  - Evidence: Detailed design documents describing each module's logic, algorithms, data structures, error handling; code structure and control flow
  - Reference: IEC 62304:2015 Section 5.4
- [sl-008] **Software Lifecycle**: Software system testing completed
  - Evidence: System test plan and results verifying software against SRS; functional testing, performance testing, stress testing; traceability to requirements
  - Reference: IEC 62304:2015 Section 5.7
- [sub-001] **Submission Documents**: 510(k) cover letter prepared and complete
  - Evidence: Signed cover letter with device name, manufacturer info, product code, predicate devices, substantial equivalence statement, and certifications
  - Reference: 21 CFR 807.85 - 510(k) Cover Letter
- [sub-004] **Submission Documents**: Substantial equivalence comparison documentation completed
  - Evidence: Detailed comparison to predicate device(s) on design, materials, performance, and intended use; explanation of any differences
  - Reference: 21 CFR 807.87(b) - Substantial Equivalence
- [sub-005] **Submission Documents**: Performance data summary prepared
  - Evidence: Summary of validation study results, algorithm performance metrics, safety data, and clinical evidence supporting device performance
  - Reference: 21 CFR 807.87(c) - Performance Data
- [sub-007] **Submission Documents**: Summary of safety and performance (SSED) prepared
  - Evidence: Comprehensive SSED document summarizing device design, non-clinical testing, clinical testing, and safety data
  - Reference: FDA 510(k) Submission Guidance
- [sub-009] **Submission Documents**: Software documentation package prepared
  - Evidence: Software lifecycle documentation: SDP, SRS, architecture, design, source code listings, test reports, risk analysis, security assessment
  - Reference: IEC 62304 + FDA SaMD Guidance

## Category Breakdown

### AI/ML-Specific
**Completion: 12.5% (1/8)**
- Complete: 1
- Partial: 3
- Missing: 4

**Incomplete Items:**
- [MAJOR] [ml-002] Model card created with algorithm documentation (PARTIAL)
  - Evidence: Model card per Mitchell et al. including: model description, intended use, performance metrics, limitations, sub-population analysis, ethical considerations
  - Reference: FDA Proposed AI/ML Regulation (2023 draft)
- [BLOCKER] [ml-003] Algorithm performance metrics established and validated (PARTIAL)
  - Evidence: Validation study with independent test set; performance metrics (sensitivity, specificity, AUROC, AUC-PR, F1 score); comparison to predicate/standard of care
  - Reference: FDA Proposed AI/ML Regulation (2023 draft)
- [MAJOR] [ml-004] Sub-population analysis completed (MISSING)
  - Evidence: Performance stratified by demographics (age, gender, race/ethnicity, comorbidities); identification of sub-populations with degraded performance; mitigation strategies
  - Reference: FDA Proposed AI/ML Regulation (2023 draft)
- [MAJOR] [ml-005] Data drift monitoring plan established (MISSING)
  - Evidence: Plan for detecting data drift post-market (feature distribution shifts, performance degradation); defined thresholds and response actions
  - Reference: FDA Proposed AI/ML Regulation (2023 draft)
- [MAJOR] [ml-006] Model retraining procedures documented (if applicable) (MISSING)
  - Evidence: For PCCP: retraining plan with data selection, labeling, validation criteria; for non-PCCP: justification that retraining is not planned
  - Reference: FDA Software as a Medical Device Action Plan (2021)
-  [ml-007] Explainability/transparency documentation (PARTIAL)
  - Evidence: Evidence of algorithm transparency (feature importance, decision rules, or other interpretability methods); user-facing documentation about how device makes decisions
  - Reference: FDA Proposed AI/ML Regulation (2023 draft)
- [BLOCKER] [ml-008] PCCP (Post-Market Continuous Learning Plan) if modifications planned (MISSING)
  - Evidence: Approved PCCP document defining pre-approved modifications, modification protocols, performance monitoring, impact assessment, or justification that PCCP not required
  - Reference: FDA Proposed AI/ML Regulation (2023 draft)

### Clinical Evidence
**Completion: 0.0% (0/4)**
- Complete: 0
- Partial: 3
- Missing: 1

**Incomplete Items:**
- [BLOCKER] [ce-001] Clinical evaluation report prepared (PARTIAL)
  - Evidence: Comprehensive clinical evaluation report reviewing literature, predicate device data, and clinical validation study results; discussion of safety and efficacy
  - Reference: 21 CFR 807.87(e) - Clinical Data
- [BLOCKER] [ce-002] Clinical validation study conducted (if required) (PARTIAL)
  - Evidence: Prospective or retrospective clinical study with predefined protocol; IRB approval; informed consent (if applicable); statistical analysis plan; results report
  - Reference: 21 CFR Part 56 - Institutional Review Boards
- [BLOCKER] [ce-003] Performance statistics documented and justified (PARTIAL)
  - Evidence: Sensitivity, specificity, predictive values, confidence intervals; comparison to predicate or reference standard; subgroup analysis; statistical power justification
  - Reference: FDA Guidance - Analytical Validation of Diagnostic Tests
- [BLOCKER] [ce-004] Substantial equivalence established (510k only) (MISSING)
  - Evidence: Substantial equivalence assessment comparing device to predicate on intended use, technology, and performance; explanation of any differences
  - Reference: 21 CFR 807.87(a) - 510(k) Summary

### Cybersecurity
**Completion: 0.0% (0/6)**
- Complete: 0
- Partial: 2
- Missing: 4

**Incomplete Items:**
- [MAJOR] [cs-001] Software bill of materials (SBOM) prepared (PARTIAL)
  - Evidence: SBOM listing all software components, libraries, and dependencies with versions and known vulnerabilities; in SPDX or CycloneDX format
  - Reference: FDA 2023 Cybersecurity Guidance
- [MAJOR] [cs-002] Threat model created and vulnerabilities identified (PARTIAL)
  - Evidence: Threat model document (STRIDE or similar); identified threats; assessment of likelihood and impact; vulnerability inventory
  - Reference: FDA 2023 Cybersecurity Guidance
- [MAJOR] [cs-003] Security testing completed (MISSING)
  - Evidence: Penetration testing results; fuzz testing; static analysis results; dynamic analysis results; evidence of remediation of identified vulnerabilities
  - Reference: FDA 2023 Cybersecurity Guidance
- [MAJOR] [cs-004] Vulnerability disclosure policy established (MISSING)
  - Evidence: Published policy describing how security researchers can report vulnerabilities; security.txt file; commitment to timely patching
  - Reference: FDA 2023 Cybersecurity Guidance
- [MAJOR] [cs-005] Incident response plan prepared (MISSING)
  - Evidence: Security incident response plan; defined roles and responsibilities; communication procedures; evidence of testing/drills
  - Reference: FDA 2023 Cybersecurity Guidance
- [MAJOR] [cs-006] Post-market cybersecurity monitoring plan established (MISSING)
  - Evidence: Plan for monitoring for security vulnerabilities post-market; defined update/patch procedures; communication plan for security updates
  - Reference: FDA 2023 Cybersecurity Guidance

### Design Controls
**Completion: 66.7% (6/9)**
- Complete: 6
- Partial: 2
- Missing: 1

**Incomplete Items:**
- [BLOCKER] [dc-003] Design outputs documented and reviewed for adequacy (PARTIAL)
  - Evidence: Design output specifications (algorithms, architecture, file formats) traced to inputs; design output review checklist
  - Reference: 21 CFR 820.30(d) - Design Output
- [BLOCKER] [dc-006] Design validation completed (does device meet user needs?) (PARTIAL)
  - Evidence: Validation plan and report; clinical testing, field studies, or real-world performance data; statistical analysis
  - Reference: 21 CFR 820.30(g) - Design Validation
- [MAJOR] [dc-007] Design transfer to production documented and verified (MISSING)
  - Evidence: Design transfer plan; evidence that manufacturing can reproducibly produce design specifications
  - Reference: 21 CFR 820.30(h) - Design Transfer

### Quality Management
**Completion: 40.0% (2/5)**
- Complete: 2
- Partial: 1
- Missing: 2

**Incomplete Items:**
- [MAJOR] [qm-002] Supplier/vendor controls established (PARTIAL)
  - Evidence: Supplier evaluation and approval procedures; purchasing specifications; supplier audit records; COTS software license tracking
  - Reference: ISO 13485:2016 Section 8.4
- [MAJOR] [qm-004] Internal audits completed (MISSING)
  - Evidence: Internal audit schedule; audit reports covering all quality system areas; audit findings and corrective actions; management review minutes
  - Reference: ISO 13485:2016 Section 8.2
-  [qm-005] Management review performed (MISSING)
  - Evidence: Management review meeting minutes; review of audit results, customer feedback, product performance, and effectiveness of corrective actions
  - Reference: ISO 13485:2016 Section 5.6

### Risk Management
**Completion: 42.9% (3/7)**
- Complete: 3
- Partial: 2
- Missing: 2

**Incomplete Items:**
- [BLOCKER] [rm-004] Risk control measures designed and evaluated (PARTIAL)
  - Evidence: Risk control plan specifying mitigation for each significant hazard; evidence of residual risk evaluation; traceability from hazard to control to design
  - Reference: ISO 14971:2019 Section 4.4
- [BLOCKER] [rm-005] Residual risk evaluation and overall risk analysis completed (PARTIAL)
  - Evidence: Residual risk report; evidence that residual risks are acceptable; overall risk benefit analysis; summary of risks considered acceptable
  - Reference: ISO 14971:2019 Section 4.5
- [BLOCKER] [rm-006] Risk management report prepared (MISSING)
  - Evidence: Comprehensive risk management report summarizing hazards, risks, controls, and residual risks; approvals from relevant stakeholders
  - Reference: ISO 14971:2019 Section 4.6
- [MAJOR] [rm-007] Post-production information monitoring plan established (MISSING)
  - Evidence: Plan for collecting and reviewing post-market data (complaints, adverse events, performance issues); defined feedback channels and review frequency
  - Reference: ISO 14971:2019 Section 4.7

### Software Lifecycle
**Completion: 70.0% (7/10)**
- Complete: 7
- Partial: 2
- Missing: 1

**Incomplete Items:**
- [BLOCKER] [sl-005] Detailed software design completed (PARTIAL)
  - Evidence: Detailed design documents describing each module's logic, algorithms, data structures, error handling; code structure and control flow
  - Reference: IEC 62304:2015 Section 5.4
- [BLOCKER] [sl-008] Software system testing completed (PARTIAL)
  - Evidence: System test plan and results verifying software against SRS; functional testing, performance testing, stress testing; traceability to requirements
  - Reference: IEC 62304:2015 Section 5.7
- [MAJOR] [sl-009] Software release procedures documented (MISSING)
  - Evidence: Release management process; version control procedures; release notes; deployment procedures; rollback procedures if applicable
  - Reference: IEC 62304:2015 Section 5.8

### Submission Documents
**Completion: 22.2% (2/9)**
- Complete: 2
- Partial: 2
- Missing: 5

**Incomplete Items:**
- [BLOCKER] [sub-001] 510(k) cover letter prepared and complete (MISSING)
  - Evidence: Signed cover letter with device name, manufacturer info, product code, predicate devices, substantial equivalence statement, and certifications
  - Reference: 21 CFR 807.85 - 510(k) Cover Letter
- [BLOCKER] [sub-004] Substantial equivalence comparison documentation completed (MISSING)
  - Evidence: Detailed comparison to predicate device(s) on design, materials, performance, and intended use; explanation of any differences
  - Reference: 21 CFR 807.87(b) - Substantial Equivalence
- [BLOCKER] [sub-005] Performance data summary prepared (PARTIAL)
  - Evidence: Summary of validation study results, algorithm performance metrics, safety data, and clinical evidence supporting device performance
  - Reference: 21 CFR 807.87(c) - Performance Data
- [MAJOR] [sub-006] Labeling and instructions for use finalized (PARTIAL)
  - Evidence: Device labeling (packaging, instructions, warnings); user manual; training materials; IFU includes all required information per 21 CFR 801
  - Reference: 21 CFR 801 - Labeling
- [BLOCKER] [sub-007] Summary of safety and performance (SSED) prepared (MISSING)
  - Evidence: Comprehensive SSED document summarizing device design, non-clinical testing, clinical testing, and safety data
  - Reference: FDA 510(k) Submission Guidance
- [MAJOR] [sub-008] Biocompatibility assessment completed (if applicable) (MISSING)
  - Evidence: Biocompatibility testing per ISO 10993 (materials, duration of contact); test reports or justification if not required
  - Reference: ISO 10993 Series - Biocompatibility
- [BLOCKER] [sub-009] Software documentation package prepared (MISSING)
  - Evidence: Software lifecycle documentation: SDP, SRS, architecture, design, source code listings, test reports, risk analysis, security assessment
  - Reference: IEC 62304 + FDA SaMD Guidance

## Summary
- **Total Items:** 58
- **Complete:** 21
- **Partial:** 17
- **Missing:** 20
- **Blocker Items:** 18
